Alligator Bioscience Logo
SE0024173637
A41BED

Alligator Bioscience

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Alligator Bioscience stops Mitazalimab development, stock plunges 74%

    Alligator Bioscience’s board has halted further independent development of the CD40 antibody Mitazalimab due to the rapidly changing treatment landscape in pancreatic cancer and intends to out-license or sell the drug. Resources will be redirected to HLX22 (anti-HER2), which is being developed externally by Shanghai Henlius Biotech; Alligator will receive revenue participation for this without development expense. The company also announced a rights issue of around SEK 125.6 million and a bridge financing; cash of SEK 33 million will only last until mid-Q3 2026. The combination of the project halt, a heavily dilutive capital measure and strained liquidity triggered the sharp share price decline. » More on de.investing.com


  • Alligator Bioscience cuts costs sharply and plans phase‑III start for mitazalimab

    Alligator Bioscience reports significant cost reductions in Q1 2026 (annualized operating costs cut from 300 to 100 million SEK; Q1 costs 17 million SEK) and reports cash of 33 million SEK. Lead candidate mitazalimab showed a 30‑month survival rate of 20% in Phase II, and the company is preparing to start a Phase‑III trial in Q4 2026; a regulatory submission is expected in Q2 2026. Because cash is only expected to last until mid‑Q3 2026, Alligator is actively exploring financing options. The stock rose 4.69% following the results. » More on de.investing.com

Financials

In the last quarter, Alligator Bioscience had revenue of €20.9k and net profit of -€1.47m
(EUR) September 2026
YoY
Revenue 20.9k 50.63%
Gross profit -1.31m -
Net profit -1.47m 32.53%
EBITDA -1.72m 155.43%

Fundamentals

Metric Value
Market capitalization
€41.96k
Number of shares
53.09m
52-week high/low
€0.11 - €0.000781
Dividends No
Beta
1.17
P/E ratio
-0.01
PEG ratio
0.00
P/B ratio
0.24
P/S ratio
1.65

Company profile

Name
Alligator Bioscience
CEO
Søren Bregenholt
Employees 11
🍪

Parqet  uses cookies. Learn more